Intra-Cellular Therapies Company Profile (NASDAQ:ITCI)

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.33. The firm had revenue of $0.11 million for the quarter, compared to analysts' expectations of $0.03 million. Intra-Cellular Therapies had a negative net margin of 32,834.94% and a negative return on equity of 27.92%. The firm's revenue for the quarter was down 52.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.71) EPS. View Intra-Cellular Therapies' Earnings History.

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Intra-Cellular Therapies.

9 equities research analysts have issued twelve-month price objectives for Intra-Cellular Therapies' shares. Their forecasts range from $10.00 to $49.00. On average, they anticipate Intra-Cellular Therapies' share price to reach $26.50 in the next twelve months. View Analyst Ratings for Intra-Cellular Therapies.

Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:

• 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (8/15/2017)
• 2. Cantor Fitzgerald analysts commented, "Investors may be waiting for Godot (the FDA). We spoke with ITCI management this morning in conjunction with the release of 2Q17 results (no call was held). They noted that the company has responded to FDA questions regarding the non-clinical toxicology findings. Perhaps off-putting to investors, but consistent with the manner in which the FDA handles such issues, ITCI is challenged in providing any time-line along which the situation could be resolved." (8/9/2017)
• 3. Cowen and Company analysts commented, "Today ITCI reported 4Q16 results." (3/1/2017)
• 4. Piper Jaffray Companies analysts commented, "With Intra-Cellular's 4Q16 call set for Weds., 3/1, we're refreshing our thesis and outlining potential outcomes of this business update. Given the 5 months since data, we'll look for visibility on four key issues: 1. Data-driven insight into factors contributing to the 302 trial failure; 2. Preliminary feedback from the FDA on the 302 trial and lumateperone (ITI-007) program; 3. The clinical and regulatory path forward for luma' over the next 12-18 months; 4. Cash required to execute on these plans." (2/23/2017)

Some companies that are related to Intra-Cellular Therapies include Dynavax Technologies Corporation (DVAX), Dermira (DERM), Xencor (XNCR), Ascendis Pharma A/S (ASND), Retrophin (RTRX), Sangamo Therapeutics (SGMO), Aduro Biotech (ADRO), Epizyme (EPZM), Five Prime Therapeutics (FPRX), Amarin Corporation PLC (AMRN), Keryx Biopharmaceuticals (KERX), Achaogen (AKAO), Insmed (INSM), ZIOPHARM Oncology (ZIOP), PTC Therapeutics (PTCT), Revance Therapeutics (RVNC), Vanda Pharmaceuticals (VNDA) and Akebia Therapeutics (AKBA).

Intra-Cellular Therapies' management team includes the folowing people:

• Lawrence J. Hineline CPA, Chief Financial Officer, Vice President - Finance, Treasurer, Assistant Secretary
• Robert E. Davis Ph.D., Senior Vice President and Chief Scientific Officer
• Michael I. Halstead, Senior Vice President, General Counsel, Secretary
• Kimberly E. Vanover Ph.D., Senior Vice President, Clinical Development
• Juan F. Sanchez M.D., Vice President - Corporate Communications
• Allen A. Fienberg Ph.D., Vice President - Business Development
• Sharon Mates Ph.D., Chairman of the Board, President, Chief Executive Officer
• Christopher D. Alafi Ph.D., Independent Director
• Richard Alan Lerner M.D., Independent Director
• Joel S. Marcus J.D. CPA, Independent Director

Intra-Cellular Therapies' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (6.27%), BB Biotech AG (4.95%), Wasatch Advisors Inc. (3.82%), State Street Corp (2.31%) and Hillhouse Capital Management Ltd. (2.30%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Michael Halstead and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

Intra-Cellular Therapies' stock was sold by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Wells Fargo & Company MN, Candriam Luxembourg S.C.A., TIAA CREF Investment Management LLC, Vanguard Group Inc., Northern Trust Corp, PDT Partners LLC and Franklin Street Advisors Inc. NC. Company insiders that have sold Intra-Cellular Therapies stock in the last year include Kimberly E Vanover, Lawrence J Hineline, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

Intra-Cellular Therapies' stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Dimensional Fund Advisors LP, Goldman Sachs Group Inc., BB Biotech AG, Samlyn Capital LLC, Federated Investors Inc. PA, State Street Corp and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought Intra-Cellular Therapies stock in the last two years include Alafi Capital Co Llc and Christopher D Alafi. View Insider Buying and Selling for Intra-Cellular Therapies.

Shares of Intra-Cellular Therapies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Intra-Cellular Therapies stock can currently be purchased for approximately $11.11.